1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Sporicidal and Sterilant Chemicals Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Sporicidal and Sterilant Chemicals Market, by Sterilant/Sporicide Type
8.1.1 Peracetic Acid Systems
8.1.1.1. Market Revenue and Forecast
8.1.2. Hydrogen Peroxide Systems
8.1.2.1. Market Revenue and Forecast
8.1.3. Glutaraldehyde & Aldehydes
8.1.3.1. Market Revenue and Forecast
8.1.4. Other Sterilants (e.g., OPA, chlorine dioxide)
8.1.4.1. Market Revenue and Forecast
9.1. Sporicidal and Sterilant Chemicals Market, by Use Mode
9.1.1. High-Level Disinfection (HLD)
9.1.1.1. Market Revenue and Forecast
9.1.2. Cold Sterilization
9.1.2.1. Market Revenue and Forecast
9.1.3. Surface Sporocidal Use
9.1.3.1. Market Revenue and Forecast
9.1.4. Other Uses
9.1.4.1. Market Revenue and Forecast
10.1. Sporicidal and Sterilant Chemicals Market, by End-Use Setting
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast
10.1.2. Ambulatory Surgery Centers
10.1.2.1. Market Revenue and Forecast
10.1.3. Dental Clinics
10.1.3.1. Market Revenue and Forecast
10.1.4. Other Settings
10.1.4.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Sterilant/Sporicide Type
11.1.2. Market Revenue and Forecast, by Use Mode
11.1.3. Market Revenue and Forecast, by End-Use Setting
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Sterilant/Sporicide Type
11.1.4.2. Market Revenue and Forecast, by Use Mode
11.1.4.3. Market Revenue and Forecast, by End-Use Setting
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Sterilant/Sporicide Type
11.1.5.2. Market Revenue and Forecast, by Use Mode
11.1.5.3. Market Revenue and Forecast, by End-Use Setting
11.2. Europe
11.2.1. Market Revenue and Forecast, by Sterilant/Sporicide Type
11.2.2. Market Revenue and Forecast, by Use Mode
11.2.3. Market Revenue and Forecast, by End-Use Setting
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Sterilant/Sporicide Type
11.2.4.2. Market Revenue and Forecast, by Use Mode
11.2.4.3. Market Revenue and Forecast, by End-Use Setting
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Sterilant/Sporicide Type
11.2.5.2. Market Revenue and Forecast, by Use Mode
11.2.5.3. Market Revenue and Forecast, by End-Use Setting
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Sterilant/Sporicide Type
11.2.6.2. Market Revenue and Forecast, by Use Mode
11.2.6.3. Market Revenue and Forecast, by End-Use Setting
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Sterilant/Sporicide Type
11.2.7.2. Market Revenue and Forecast, by Use Mode
11.2.7.3. Market Revenue and Forecast, by End-Use Setting
11.3. APAC
11.3.1. Market Revenue and Forecast, by Sterilant/Sporicide Type
11.3.2. Market Revenue and Forecast, by Use Mode
11.3.3. Market Revenue and Forecast, by End-Use Setting
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Sterilant/Sporicide Type
11.3.4.2. Market Revenue and Forecast, by Use Mode
11.3.4.3. Market Revenue and Forecast, by End-Use Setting
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Sterilant/Sporicide Type
11.3.5.2. Market Revenue and Forecast, by Use Mode
11.3.5.3. Market Revenue and Forecast, by End-Use Setting
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Sterilant/Sporicide Type
11.3.6.2. Market Revenue and Forecast, by Use Mode
11.3.6.3. Market Revenue and Forecast, by End-Use Setting
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Sterilant/Sporicide Type
11.3.7.2. Market Revenue and Forecast, by Use Mode
11.3.7.3. Market Revenue and Forecast, by End-Use Setting
11.4. MEA
11.4.1. Market Revenue and Forecast, by Sterilant/Sporicide Type
11.4.2. Market Revenue and Forecast, by Use Mode
11.4.3. Market Revenue and Forecast, by End-Use Setting
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Sterilant/Sporicide Type
11.4.4.2. Market Revenue and Forecast, by Use Mode
11.4.4.3. Market Revenue and Forecast, by End-Use Setting
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Sterilant/Sporicide Type
11.4.5.2. Market Revenue and Forecast, by Use Mode
11.4.5.3. Market Revenue and Forecast, by End-Use Setting
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Sterilant/Sporicide Type
11.4.6.2. Market Revenue and Forecast, by Use Mode
11.4.6.3. Market Revenue and Forecast, by End-Use Setting
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Sterilant/Sporicide Type
11.4.7.2. Market Revenue and Forecast, by Use Mode
11.4.7.3. Market Revenue and Forecast, by End-Use Setting
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Sterilant/Sporicide Type
11.5.2. Market Revenue and Forecast, by Use Mode
11.5.3. Market Revenue and Forecast, by End-Use Setting
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Sterilant/Sporicide Type
11.5.4.2. Market Revenue and Forecast, by Use Mode
11.5.4.3. Market Revenue and Forecast, by End-Use Setting
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Sterilant/Sporicide Type
11.5.5.2. Market Revenue and Forecast, by Use Mode
11.5.5.3. Market Revenue and Forecast, by End-Use Setting
12.1. 3M
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Advanced Sterilization Products (ASP)
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Cantel (STERIS)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Ecolab
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Getinge
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Metrex
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Paul Hartmann
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Reckitt
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Schülke & Mayr
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. STERIS
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
